Sarepta's Duchenne gene therapy wins OK; FDA spurns NASH drug; Eli Lilly buys DICE for $2.4B; The new antitrust landscape; and more
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.
The Endpoints 11 is back. This year, John Carroll will be teaming up with Drew Armstrong, Ryan Cross, Andrew Dunn and Kyle LaHucik to select and profile the 2023 edition of our annual report on some of the most promising private biotechs out there. Nominate your favorite biotech here.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.